Evidence map›Paper›PMID 35427834›Full record

ArticleESMO open2022

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

M Mark, S Rusakiewicz, M Früh, S Hayoz, F Grosso, M Pless, P Zucali, G L Ceresoli, A Maconi, M Schneider and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 2 countries.

M MarkDepartment of Oncology/Haematology, Kantonsspital Graubünden, Chur, Switzerland. Electronic address: michael.mark@ksgr.ch.
S RusakiewiczCenter of Experimental Therapeutics, Department of Oncology UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Department of Oncology, UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland.
M FrühDepartment of Medical Oncology and Haematology, St. Gallen, Switzerland; University of Bern, Bern, Switzerland; Department of Medical Oncology, University of Bern, Bern, Switzerland.
S HayozSAKK Coordinating Centre, Bern, Switzerland.
F GrossoMesothelioma Unit e Oncology, SS. Antonio and C. Arrigo Hospital, Alessandria, Italy.
M PlessDepartment of Medical Oncology and Haematology, Kantonsspital Winterthur, Winterthur, Switzerland.
P ZucaliDepartment of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
G L CeresoliOncology Unit, Humanitas Gavazzeni Clinic, Bergamo, Italy.
A MaconiResearch Training Innovation Infrastructure, Research Innovation Department, Azienda Ospedaliera "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy.
M SchneiderSAKK Coordinating Centre, Bern, Switzerland.
P FroeschOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
D TarussioCenter of Experimental Therapeutics, Department of Oncology UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Department of Oncology, UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland.
F BenedettiCenter of Experimental Therapeutics, Department of Oncology UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Department of Oncology, UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland.
J DagherInstitute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
L KandalaftCenter of Experimental Therapeutics, Department of Oncology UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Department of Oncology, UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland.
R von MoosDepartment of Oncology/Haematology, Kantonsspital Graubünden, Chur, Switzerland.
S Tissot-RenaudCenter of Experimental Therapeutics, Department of Oncology UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Department of Oncology, UNIL CHUV, Lausanne University Hospital, Lausanne, Switzerland.
S SchmidDepartment of Medical Oncology and Haematology, St. Gallen, Switzerland; University of Bern, Bern, Switzerland.
Y MetaxasDepartment of Haematology and Oncology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
University of Lausanne · CHAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITKantonsspital Graubünden · CHLudwig Cancer Research · CHSwiss Group For Clinical Cancer Research · CHHumanitas Gavazzeni · ITInstitute of Oncology Research · CHIRCCS Humanitas Research Hospital · ITKantonsspital Münsterlingen · CHKantonsspital Winterthur · CHSt. Gallen Oncology Conferences · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SAKK 17/16 study showed promising efficacy data with lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma. Here, we evaluated long-term outcome and analyzed the impact of lurbinectedin monotherapy on the tumor microenvironment at the cellular and molecular level to predict outcomes. MATERIAL AND

methodsForty-two patients were treated with lurbinectedin in this single-arm study. Twenty-nine samples were available at baseline, and seven additional matched samples at day one of cycle two of treatment. Survival curves and rates between groups were compared using the log-rank test and Kaplan-Meier method. Statistical significance was set at P value <0.05.

resultsUpdated median overall survival (OS) was slightly increased to 11.5 months [95% confidence interval (CI) 8.8-13.8 months]. Thirty-six patients (85%) had died. The OS rate at 12 and 18 months was 47% (95% CI 32.1% to 61.6%) and 31% (95% CI 17.8% to 45.0%), respectively. Median progression-free survival was 4.1 months (95% CI 2.6-5.5 months). No new safety signals were observed. Patients with lower frequencies of regulatory T cells, as well as lower tumor-associated macrophages (TAMs) at baseline, had a better OS. Comparing matched biopsies, a decrease of M2 macrophages was observed in five out of seven patients after exposure to lurbinectedin, and two out of four patients showed increased CD8+ T-cell infiltrates in tumor. DISCUSSION: Lurbinectedin continues to be active in patients with progressing malignant pleural mesothelioma. According to our very small sample size, we hypothesize that baseline TAMs and regulatory T cells are associated with survival. Lurbinectedin seems to inhibit conversion of TAMs to M2 phenotype in humans.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantCarbolinesHeterocyclic Compounds, 4 or More RingsHumansPalliative CareTumor MicroenvironmentCarbolinesHeterocyclic Compounds, 4 or More RingsPM 01183lurbinectedinM2 phenotypemalignant pleural mesotheliomaregulatory T cellstumor-associated macrophagestumor-infiltrating lymphocytes

Identifiers

PMID35427834
PMCPMC9271468
OpenAlexW4223623651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.